A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients

The purpose of this study is to assess the effectivemenss of durvalumab plus tremelimumab in combination with chemotherapy complated with pembrolizumab in combination with chemotherapy (pemetrexed) in participants with metastaic lung cancer containing certain mutations. 

For more information visit:
https://clinicaltrials.gov/ct2/show/NCT06008093

Inova Schar Cancer 
8081 Innovation Park Drive
Fairfax, VA  22031

• Participant must be ≥ 18 years at the time of signing the
• Histologically or cytologically documented Stage IV non-squamous NSCLC not amenable to curative surgery or radiation.
• No prior chemotherapy or any other systemic therapy for metastatic NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, provided that progression has occurred > 6 months from end of last therapy.
• Additional eligibility in protocol

• As judged by the Investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diseases, active infection, active ILD/pneumonitis, serious chronic gastrointestinal conditions associated with diarrhea, psychiatric illness/social situations), chronic diverticulitis or previous complicated diverticulitis (with the exception of diverticulosis), or history of allogenic organ transplant, which, in the Investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
• Mixed small cell lung cancer and NSCLC
• No radiation therapy is allowed, unless it is:
  • definitive radiation that had been administered at least 6 months prior,
  • palliative radiation to brain, with associated criteria for stability or lack of symptoms, or
  • palliative radiation to painful bony lesions (this must comprise less than 30% of bone marrow).
• Additional ineligibility in protocol